The study, conducted by the Mayo Clinic, Johns Hopkins School of Medicine and medical device manufacturer TYRX, found patients with cardiac device-associated infections had triple the length of hospital stay, 55-118 percent higher hospitalization costs, 8-11 times the rate of in-hospital mortality and twice the mortality a year after admission compared to patients implanted with a pacemaker or defibrillator who did not contract an infection.
Read the TYRX release on infections associated with cardiac devices (pdf).
Read more coverage on infection control:
– CDC Updates Bloodstream Infection Prevention Guidelines
– Hospital Nabs Top Recognition Despite Criticism for High Infection Rates, Fraud
– Dr. Edo McGowan Responds to Study Indicating MRSA Infection May Be Seasonal
